ClinicalTrials.gg
RecruitingNCT05363397STARSUpdated Dec 1, 2025

Safety and Tolerability of Adjunctive TBO-309 in Reperfusion for Stroke

A Phase 2 interventional study of TBO-309 in Acute Ischemic Stroke, sponsored by The Florey Institute of Neuroscience and Mental Health. Recruiting at 7 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by The Florey Institute of Neuroscience and Mental Health · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Sep 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 62 studies in Ischemic Stroke with a site in Australia — 17 open to participants now, 20 under way, 8 of them phase 3. Ischemic Stroke · Australia.

Planned enrollment
44th of 55
80 · median 300
Started
2023
with 5 others
Phase 2
18 of 62
3 open now
Primary completion
2026-02
later than 1 of 19 live
Registered
41st of 62
by date
Lead sponsor
3 of 62
The Florey Institute of Neuroscience and Mental Health

Among the 62 studies in Ischemic Stroke with a site in Australia, this one is the 44th largest by planned enrollment of the 55 interventional ones that give a count, is one of 6 that started in 2023, is one of 18 in phase 2, reaches primary completion later than 1 of the 19 other live ones, and was the 41st registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

17 of the 62 studies in Ischemic Stroke with a site in Australia are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Ischemic Stroke with a site in Australia, or all of them as a file.
02

Study summary

STARS is a prospective, multicentre, open-label, dose escalation, Phase IIa study to assess the safety and tolerability of TBO-309, an adjuvant antiplatelet therapy, in patients with AIS.

Acute ischaemic stroke (AIS) is caused by a severe blockage of an artery leading to immediate reduced blood flow to part of the brain. Standard therapies target the blocked artery by either dissolving the blockage or removing the blockage. However, even after successful treatment, re-blockage of arteries can occur. The use of an antiplatelet therapy, TBO-309, in addition to standard therapies offers the possibility of improved restoration of blood flow and reduced rates of artery re-blockage.

Read the detailed description

Stroke is a leading cause of disability worldwide, with most strokes in Australia being Acute ischaemic stroke (AIS). AIS is caused by a severe blockage of an artery leading to immediate reduced blood flow to part of the brain. Timely restoration of blood flow is critical to preserve brain function. Standard therapies target the blocked artery by either dissolving the blockage (intravenous thrombolysis (IVT)) or removing the blockage (endovascular thrombectomy (EVT)). However, even after successful treatment, re-blockage of arteries can occur. The use of an antiplatelet therapy in addition to IVT/EVT offers the possibility of improved restoration of blood flow and reduced rates of artery re-blockage.

STARS is a prospective, multicentre, open-label, dose escalation, Phase IIa study to assess the safety and tolerability of TBO-309, an adjuvant antiplatelet therapy, in patients with AIS. The study will test the hypothesis that AIS patients who are treated with TBO-309 in conjunction with standard therapy (IVT alone or IVT + EVT) will not experience higher rates of ICH compared to the expected rates of ICH in patients treated with only standard therapy (IVT alone or IVT + EVT).

TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation, thereby specifically inhibiting thrombosis without interfering with normal haemostasis. In order to evaluate safety at lower doses, four dose levels in total will be administered using a serial dose-escalation design. Doses will be assigned based on a dose escalation methodology commencing with lower doses assigned early in the study. As safety criteria are satisfied (based on ICH rates) doses will be increased. The dosage strength of TBO-309 to be administered (30mg, 60mg, 120mg or 180mg) will be assigned by the study database.

Patients presenting to hospital with an AIS will be assessed according to the trial inclusion and exclusion criteria by the Principal Investigator, or nominated delegate, on admission to the Emergency Department. Consent will be sought from either the patient or their Person Responsible/Medical Treatment Decision Maker prior to enrolment into the study. Standard therapy, either IVT alone or IVT + EVT, will commence and the TBO-309 will be administered at the same time as standard therapy. Following administration of study drug and treatment with standard therapies, patients will receive usual supportive care either in the Intensive Care Unit or in the hospital ward. Any significant neurological deterioration will require an emergency non-contrast CT head to assess for the presence of ICH. All patients will receive a 24-36 hour MRI or a multimodal CT to assess asymptomatic bleeding, recanalisation and infarct volume.

During the patients hospital stay clinical outcome data will be collected during the study period to document response to treatment and to monitor safety. Study patients will be followed-up for 90 days post-enrolment, or to death, whichever is the earlier.

03

Conditions studied

  • Acute Ischemic Stroke

Keywords

  • Antiplatelet therapy
  • Stroke
  • Blood clot
  • Intravenous thrombolysis (IVT)
  • Endovascular Thrombectomy (EVT)
  • TBO-309
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patient aged 18 years or more
  2. Patient has an acute ischaemic stroke
  3. Patient will be treated with either:

    1. Intravenous thrombolysis (IVT) with alteplase or tenecteplase for a diagnosis of AIS that is confirmed by CT imaging;

      alone/OR WITH

    2. Endovascular Thrombectomy (EVT) for large vessel occlusion (LVO) in the internal carotid artery, middle cerebral artery (M1 segment), middle cerebral artery (M2 segment) or with tandem occlusion of both the cervical carotid and intracranial large arteries who either:

    i. presented within 6 hours of stroke onset

    OR

    ii. presented between 6-24 hours after they were last known to be well and clinical observations and either CT perfusion or MRI features indicate the presence of salvageable brain tissue, defined as ischaemic core \<70mL with a mismatch ratio >1.8 and absolute mismatch >15mL.

  4. Patient has at least a mild grade of neurological impairment i.e. NIHSS of 5 or more
  5. Patient has an estimated pre-stroke mRS of less than 4

Exclusion criteria

Exclusion Criteria

  1. Patient is considered unlikely to benefit from study intervention defined by one of the following:

    1. Advanced dementia
    2. Severe pre-stroke disability (mRS score 4-5)
    3. Glasgow Coma Score (GCS) 3 to 5
    4. Evidence of a large well-defined ischaemic lesion measuring more than one third of the MCA territory
  2. High likelihood of undergoing stent insertion and requiring additional antithrombotic(s)
  3. Uncontrolled hypertension (SBP >180 or DBP >110, to medical therapy)
  4. ICH within the last 90 days
  5. Myocardial infarction or stroke within the last 30 days
  6. Patient has an underlying disease process with a of \<90 days
  7. to thrombolysis i.e. increased bleeding risk
  8. Contraindication to intravenous contrast agents including renal impairment or allergy
  9. Known treatment with dual antiplatelet therapy or anticoagulant medication
  10. Known severe liver disease
  11. Known bleeding disorder
  12. Cardiopulmonary resuscitation or arterial puncture at non-compressible site or lumbar puncture within 7 days
  13. Another medical illness or social circumstance that may interfere with outcome assessments and follow-up
  14. Known or suspected pregnancy
  15. Patients currently participating in another interventional clinical trial
  16. unable to be obtained from the patient or their Person Responsible/Medical Treatment Decision Maker prior to study interventions
  17. Study drug cannot be given within one hour of thrombolytic drug bolus
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
Single (Outcomes assessor)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    TBO-309 30mg (25% of target dose)

    Following randomisation, 30mg TBO-309 will be administered at the same time as the rt-PA infusion or tenecteplase bolus (as part of intravenous thrombolysis) or as soon as practical. The allocated dose of TBO-309 will be given intravenously as follows: * 20% of the dose will be administered as a bolus over approximately one minute; then * the remainder of the dose (80%) will be administered over 3 hours as an infusion Only one dose will be administered to the patient.

    Drug: TBO-309

  • Experimental
    TBO-309 60mg (50% of target dose)

    Following randomisation, 60mg TBO-309 will be administered at the same time as the rt-PA infusion or tenecteplase bolus (as part of intravenous thrombolysis) or as soon as practical. The allocated dose of TBO-309 will be given intravenously as follows: * 20% of the dose will be administered as a bolus over approximately one minute; then * the remainder of the dose (80%) will be administered over 3 hours as an infusion Only one dose will be administered to the patient.

    Drug: TBO-309

  • Experimental
    TBO-309 120mg (100% of target dose)

    Following randomisation, 120mg TBO-309 will be administered at the same time as the rt-PA infusion or tenecteplase bolus (as part of intravenous thrombolysis) or as soon as practical. The allocated dose of TBO-309 will be given intravenously as follows: * 20% of the dose will be administered as a bolus over approximately one minute; then * the remainder of the dose (80%) will be administered over 3 hours as an infusion Only one dose will be administered to the patient.

    Drug: TBO-309

  • Experimental
    TBO-309 180mg (150% of target dose)

    Following randomisation, 180mg TBO-309 will be administered at the same time as the rt-PA infusion or tenecteplase bolus (as part of intravenous thrombolysis) or as soon as practical. The allocated dose of TBO-309 will be given intravenously as follows: * 20% of the dose will be administered as a bolus over approximately one minute; then * the remainder of the dose (80%) will be administered over 3 hours as an infusion Only one dose will be administered to the patient.

    Drug: TBO-309

Interventions

  • DrugTBO-309

    TBO-309 is a potent, selective and ATP competitive PI3Kβ inhibitor which blocks platelet activation adhesion/aggregation and promotes platelet disaggregation, thereby specifically inhibiting thrombosis without interfering with normal haemostasis.

06

What researchers measure

Primary outcomes

  1. Proportion of patients with ICH within 24-36 hours of study drug (TBO-309) commencement.

    Proportion of patients with ICH within 24-36 hours of study drug (TBO-309) commencement. ICH is defined as parenchymal haemorrhage (PH) type II based on The Heidelberg Bleeding Classification or any intracranial haemorrhage leading to clinical deterioration i.e. an increase in NIHSS of 4 points or more, on post-intervention brain MRI with MRA or multimodal CT scan (see appendix 2 and 3). This definition allows the inclusion of any clinically and radiologically significant haemorrhage with the rate of expected ICH in this patient population estimated to be up to 8%

    Time frame: Within 24-36 hours of initiation of study drug

Secondary outcomes

  1. All bleeding

    All bleeding within 72 hours of study drug (TBO-309) administration according to a modified WHO scale

    Time frame: Within 72 hours of study drug administration

  2. All ICH

    All ICH demonstrated on 24-36 hours imaging (recommended in patients who did not have the 2-6 hours imaging)

    Time frame: 24-36 hours

  3. All intracerebral hemorrhage (ICH)

    All ICH as demonstrated on CT/MRI up to 90 days

    Time frame: Up to 90 days post study drug administration

  4. All bleeding

    All bleeding reported up to 90 days according to a modified WHO scale

    Time frame: Up to 90 days post study drug administration

Other outcomes

  1. Recanalisation rate

    CT Angiogram (CTA) or MR Angiogram (MRA) assessment 2-6 hours post study drug commencement in patients with visible vessel occlusion who do not receive endovascular thrombectomy to measure recanalisation rate by the Arterial Occlusive Lesion (AOL) scale

    Time frame: Within 2-6 hours of study drug commencement

  2. Reperfusion rates

    Reperfusion rates by expanded Thrombolysis in Cerebral Infarction scale (eTICI) 2b50 or better (i.e. 50% to 100%) at the initial catheter angiogram in patients receiving endovascular thrombectomy and at the end after patients have received endovascular thrombectomy.

    Time frame: Post EVT

  3. Infarct volume

    Infarct volume 24-36 hours post study drug commencement measured by Diffusion Weighted Imaging (DWI) MRI or CT scan

    Time frame: 24-36 hours post study drug commencement

  4. NIHSS score

    Quantifies stroke severity

    Time frame: At 24 hours, 72 hours and 7 days post study drug administration or hospital discharge (whichever is sooner)

  5. Modified Rankin Scale (mRS) score

    Measures the degree of disability or dependence in the daily activities of people who have suffered a stroke.

    Time frame: At hospital discharge and 90 days post study drug administration

  6. Mortality

    All-cause mortality

    Time frame: At 90 days post study drug administration

  7. Plasma levels of TBO-309

    Plasma levels of TBO-309 will be measured to generate a population pharmacokinetic model

    Time frame: At the end of infusion, and 1 and 3 hours post end of infusion

  8. AKT phosphorylation relative to total AKT

    AKT phosphorylation relative to total AKT (pAKT/AKT) from platelets at the end of infusion

    Time frame: At the end of infusion

  9. Genomic markers

    Genomic markers of delayed TBO-309 clearance when individuals with delayed clearance are identified

    Time frame: 24 hours post end of infusion

  10. Genetic markers for stroke outcome

    Putative genetic markers for stroke outcome, including bleeding and reperfusion, following TBO-309 administration

    Time frame: 24 hours post end of infusion

07

Study locations

7 of 7 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2023 (actual). Primary completion is estimated for Feb 2026, 28 months after the start.

Of 82 non-industry phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 40. This study's planned 28 months is close to that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
May 2, 2022
First posted
May 5, 2022
StartActual
Sep 27, 2023
Primary completionEst.
Feb 1, 2026
CompletionEst.
May 1, 2026
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05363397
Lead sponsor
The Florey Institute of Neuroscience and Mental Health
Collaborators
Neuroscience Trials Australia
Responsible party
Sponsor
First posted
May 5, 2022
Start date
Sep 27, 2023
Primary completion
Feb 1, 2026 (estimated)
Completion
May 1, 2026 (estimated)
Last update
Dec 1, 2025

Study contacts

Candice Delcourt, Dr
Contact
cdelcourt@georgeinstitute.org.au
+61 2 8052 4601
Michele Sallaberger
Contact
michele.sallaberger@florey.edu.au
+61 438471423
Candice Delcourt, Dr
study chair · The George Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion